Amalgamated Financial’s Lexicon Pharmaceuticals LXRX Stock Holding History

Amalgamated Financial’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$20K	Buy	+9,621	New	+$26.7K	﹤0.01%	2750

Other funds holding LXRX

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amalgamated Financial's LXRX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Lexicon Pharmaceuticals (LXRX) in Q1 2022: 9,621 shares worth $20K. The stake represents ﹤0.01% of the portfolio and ranks #2750 among its holdings.

101 funds tracked by Wall St. Rank hold LXRX as of Q1 2022.

Amalgamated Financial held 9,621 shares of Lexicon Pharmaceuticals worth $20K as of Q1 2022.
Lexicon Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
Lexicon Pharmaceuticals made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2750 holding.
101 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.